After Alzheimer’s disease, Parkinson’s disease (PD) is the most common, neurodegenerative condition affecting around 0.5-1% of the population between the ages of 65-69. OBD has evaluated the epigenetic read-outs on the loci of the genetic, epigenetic, and protein markers that had been previously identified and independently linked to Parkinson’s disease using the EpiSwitch™ platform technology. Biomarkers suitable for differentiation between PD patients and controls were identified including biomarkers in the loci highly sensitive microtubule-associated protein tau (MAPT), α-synuclein (SNCA) and serine/arginine repetitive matrix 2 (SRRM2). This led to a complete and accurate discrimination between the two groups and shows the utility of this test for further development of a PD diagnostic.